Evidence map›Paper›PMID 41676391›Full record

ArticleJournal of translational autoimmunity2026

Antinuclear antibody targets in autoimmune hepatitis and drug-induced liver injury: Diagnostic relevance of nucleosome antibodies.

Mirjam Kolev, Michèle Freiburghaus, Guido Stirnimann, Henning Nilius, Martin Wartenberg, Juliette Schlatter, Michael Nagler, Michael P Horn, Nasser Semmo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mirjam KolevDepartment of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Michèle FreiburghausDepartment of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Guido StirnimannDepartment of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Henning NiliusDepartment of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Martin WartenbergInstitute of Tissue Medicine and Pathology, University of Bern, Switzerland.
Juliette SchlatterDepartment of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Michael NaglerDepartment of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Michael P HornDepartment of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Nasser SemmoDepartment of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Anti-nuclear antibodies (ANA) are detected in 70-100 % of patients with autoimmune hepatitis (AIH) and in 22-33 % of patients with drug-induced liver injury (DILI). However, little is known about the specific antigens which they bind to. This study aimed to investigate the antigen specificity of ANA in patients with AIH and DILI and to assess the diagnostic value of these antibodies in differentiating between the two diseases. Methods: We performed a retrospective, cross-sectional analysis of ANA-positive patients with AIH or DILI treated at a tertiary referral center. ANA patterns were determined by indirect immunofluorescence, followed by antigen-specific characterization using ELISA. Results: A total of 81 patients were included (54 AIH, 27 DILI). A homogeneous ANA pattern was more frequently observed in AIH (75.9 %) than in DILI (48.1 %). Among patients with a homogeneous pattern, anti-nucleosome antibodies were present in 51.2 % of AIH patients and 15.4 % of DILI patients, yielding a specificity of 84.6 % (95 % confidence interval (CI) 54.6-98.1) and a sensitivity of 51.2 % (95 % CI: 35.1-67.1). Anti-nucleosome antibodies demonstrated the highest diagnostic accuracy in this subgroup (area under the curve (AUROC): 0.85; 95 % CI: 0.70-1.00), outperforming or equaling Immunoglobulin G (IgG) (AUROC: 0.85; 95 % CI: 0.74, 0.95), anti-F-actin antibodies (AUROC: 0.81; 95 % CI: 0.69, 0.93) and anti-smooth muscle antibodies (SMA) (AUROC: 0.80; 95 % CI: 0.67, 0.92). Conclusions: In ANA-positive patients with a homogeneous ANA pattern, anti-nucleosome antibodies provide high diagnostic accuracy in distinguishing AIH from DILI. These findings suggest that anti-nucleosome antibodies may aid in the diagnostic workup of ANA-positive liver injury.

Indexed as

Anti-histone antibodiesAnti-nuclear antibodiesAnti-nucleosome antibodiesAutoimmune hepatitisDrug-induced liver injury

Identifiers

PMID41676391
PMCPMC12886071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.